FrancophonIA/ELRC3.0 huggingface dataset:
English: pollakiuria, urinary retention, dysuria
Estonian: Neerude ja kuseteede häired uriinipidamatus, pollakisuuria, uriinipeetus, düsuuria
English: Butyl hydroxytoluene (E321) Polyethylene oxide 7000K Ferric oxide (red) (E172) Ferric oxide (yellow) (E172) Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate
Estonian: Butüülhüdroksütolueen (E321) Polüetüleenoksiid 7000K Raudoksiid (punane) (E172) Raudoksiid (kollane) (E172) Hüdroksüetüültselluloos Polüetüleenglükool 3350 Tselluloosatsetaat
English: Butyl hydroxytoluene (E321) Ferric oxide (yellow) (E172) Polyethylene oxide 7000K Ferric oxide (red) (E172) Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate
Estonian: Butüülhüdroksütolueen (E321) Raudoksiid (kollane) (E172) Polüetüleenoksiid 7000K Raudoksiid (punane) (E172) Hüdroksüetüültselluloos Polüetüleenglükool 3350 Tselluloosatsetaat
English: • dizziness
Estonian: • janutunne
English: • sensation of spinning (vertigo).
Estonian: • pöörlemistunne (vertiigo).
English: R076477-SCA-3002
Estonian: R076477-SCH-3002
English: 14 prolonged-release tablets - EU/1/07/395/076 28 prolonged-release tablets - EU/1/07/395/053 49 prolonged-release tablets - EU/1/07/395/054 56 prolonged-release tablets - EU/1/07/395/055 98 prolonged-release tablets - EU/1/07/395/056
Estonian: 49 toimeainet prolongeeritult vabastavat tabletti - EU/1/07/395/054 56 toimeainet prolongeeritult vabastavat tabletti - EU/1/07/395/055 98 toimeainet prolongeeritult vabastavat tabletti - EU/1/07/395/056
English: Consideration should be given to the prolonged-release nature of the product when assessing treatment needs and recovery.
Estonian: Ravivajaduse ja paranemise hindamisel peab arvesse võtma, et tegemist on toimeainet prolongeeritult vabastava ravimvormiga.
English: Butyl hydroxytoluene (E321) Polyethylene oxide 7000K Ferric oxide (red) (E172) Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate
Estonian: Butüülhüdroksütolueen (E321) Polüetüleenoksiid 7000K Raudoksiid (punane) (E172) Hüdroksüetüültselluloos Polüetüleenglükool 3350 Tselluloosatsetaat
English: Bucureşti-Ploieşti Nr. 1A, Clădirea C1, Etaj 3, Sector 1, Bucureşti Romania
Estonian: Bucureşti-Ploieşti Nr. 1A, Clădirea C1, Etaj 3, Sector 1, Bucureşti Rumeenia
English: Annex I List of the names, pharmaceutical form, strength of the medicinal products, route of administration, Marketing Authorisation Holders in the Member States
Estonian: Lisa I Ravimite nimetuste, ravimvormi, tugevuse, manustamisviisi, müügiloa hoidjate loetelu liikmesriikides
English: Heinzelova 62a 10 000 Zagreb Croatia
Estonian: Heinzelova 62a 10 000 Zagreb Horvaatia
English: 00-867 Warszawa Poland
Estonian: 00-867 Warszawa Poola
English: 174 56 Alimos Greece
Estonian: 174 56 Alimos Kreeka
English: Via Vitorchiano 151 00189 Roma Italy
Estonian: Via Vitorchiano 151 00189 Roma Itaalia
English: 34 avenue Léonard de Vinci 92400 Courbevoie France
Estonian: 34 avenue Léonard de Vinci 92400 Courbevoie Prantsusmaa
English: Šmartinska cesta 140 1000 Ljubljana Slovenia
Estonian: Šmartinska cesta 140 1000 Ljubljana Sloveenia
English: Malesci Istituto Farmacobiologico S.p.A Via Lungo l'Ema 7 Bagno a Ripoli (FI) Italy
Estonian: Malesci Istituto Farmacobiologico S.p.A Via Lungo l'Ema 7 Bagno a Ripoli (FI) Itaalia
English: Red Oak North South County Business Park Leopardstown
Estonian: South County Business Park Leopardstown
English: 0.05% w/w Mometasone furoate (monohydrate) calculated on the anhydrous basis
Estonian: 0,05% kaalu järgi mometasoonfuroaati (monohüdraat) arvutatud veevaba aine alusel
English: Belgium MSD Belgium BVBA/SPRL Clos du Lynx 5
Estonian: MSD Belgium BVBA/SPRL Clos du Lynx 5
English: Luxembourg MSD Belgium BVBA/SPRL Clos du Lynx 5
Estonian: Luksemburg MSD Belgium BVBA/SPRL Clos du Lynx 5
English: Merck Sharp & Dohme Ireland (Human Health) Limited
Estonian: Merck Sharp & Dohme Ireland (Human Health) Limited Red Oak North
English: Denmark Merck Sharp & Dohme BV Waarderweg 39
Estonian: Merck Sharp & Dohme BV Waarderweg 39
English: Merck Sharp & Dohme Ltd Hertford Road Hoddesdon
Estonian: Ühendkuningriik Merck Sharp & Dohme Ltd Hertford Road
English: Germany MSD SHARP & DOHME GMBH
Estonian: MSD SHARP & DOHME GMBH Lindenplatz 1
English: In the MRP the United Kingdom is the Reference Member State and Austria, Belgium, Denmark, Finland, France, Greece, Germany, Italy, Ireland, Iceland, Luxembourg, The Netherlands, Portugal, Spain and Sweden are Concerned Member States.
Estonian: Viiteliikmesriigiks on vastastikuse tunnustamise menetluses Ühendkuningriik ning puudutatud liikmesriikideks on Austria, Belgia, Taani, Soome, Prantsusmaa, Kreeka, Saksamaa, Itaalia, Iirimaa, Island, Luksemburg, Madalmaad, Portugal, Hispaania ning Rootsi.
English: Germany atmadisc
Estonian: Saksamaa atmadisc
English: 15232 Halandri, Athens Greece
Estonian: 15232 Halandri, Athens, Kreeka
English: In several EU Member States Seretide Evohaler and associated names (see Annex I) are approved through the Mutual Recognition Procedure (MRP).
Estonian: Mõnedes ELi liikmesriikides on Seretide Evohaler ja sarnased nimetused (vt I lisa) vastastikuse tunnustamise menetluse kaudu heaks kiidetud.
English: Box 24 FIN-02231, Espoo Finland
Estonian: Box 24, FIN-02231 Espoo, Soome
English: Note: Seretide 25/50 microgram strength is not appropriate in adults and children with severe asthma.
Estonian: Märkus: SERETIDE 25/50 µg tugevus ei sobi täiskasvanutele ja raske astmaga lastele.
English: Do not stop taking Seretide suddenly as this could make your asthma worse and could cause problems with the body's hormones.
Estonian: Ärge lõpetage Seretide manustamist järsku, kuna teie astma võib halveneda ning tekkida võivad nihked organismi hormonaalsüsteemis.
English: Treatment with Seretide should not be stopped abruptly.
Estonian: Ravi SERETIDE'ga ei tohi lõpetada järsku.
English: OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF SERETIDE EVOHALER AND ASSOCIATED NAMES (SEE ANNEX I)
Estonian: SERETIDE EVOHALERi JA SARNASTE NIMETUSTE (VT I LISA) TEADUSLIKU HINDAMISE ÜLDKOKKUVÕTE
English: • the CHMP considered the referral made under Article 6(13) of Commission Regulation (EC) N 1084/2003 for Seretide Evohaler and associated names (see Annex I)
Estonian: • inimtervishoius kasutatavate ravimite komitee kaalus komisjoni määruse (EÜ) nr 1084/2003 artikli 6 lõike 13 alusel tehtud esildist Seretide Evohaleri ja sarnaste nimetuste (vt I lisa) kohta;
English: Do not store Seretide Evohaler in a cold place, as your medicine may not work as well.
Estonian: Ärge hoidke Seretide Evohaler'it külmas kohas, kuna ravimi toime võib väheneda.
English: United Kingdom Glaxo Wellcome UK Limited, Stockley Park West, Uxbridge Middlesex UB11 1BT
Estonian: Ühendkuningriik Glaxo Wellcome UK Limited, trading as Allen & Hanburys Stockley Park West, Uxbridge, Middlesex UB11 1BT,
English: GlaxoSmithKline ehf Thverholt 14, 105 Reykjavik Iceland
Estonian: GlaxoSmithKline ehf Thverholt 14, 105 Reykjavik, Island
English: Seretide Evohaler should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.
Estonian: SERETIDE kasutamine tuleb otsekohe lõpetada, hinnata patsiendi seisundit ning vajadusel rakendada alternatiivset ravi.
English: Care should be taken when transferring patients to Seretide therapy, particularly if there is any reason to suppose that adrenal function is impaired from previous systemic steroid therapy.
Estonian: Patsientide üleviimine SERETIDE-ravile peab toimuma ettevaatusega, eriti kui on põhjust arvata, et neerupealiste funktsioon on eelneva süsteemse hormoonravi poolt pärsitud.
English: If Seretide therapy has to be withdrawn due to overdose of the beta agonist component of the drug, provision of appropriate replacement steroid therapy should be considered.
Estonian: Kui SERETIDE-ravi jäetakse ära ravimi βagonist komponendi üleannustamise tõttu, tuleb kaaluda steroidkomponendi asendust.
English: There are no data available for use of Seretide inhaler in children aged under 4 years.
Estonian: Puuduvad andmed ravimi kasutamise kohta alla 4-aastastel lastel.
English: What Seretide looks like and contents of the pack Pressurised inhalation, suspension.
Estonian: Kuidas Seretide välja näeb ja pakendi sisu Inhaleeritav aerosool, suspensioon.
English: The time on treatment for 50% of subjects to achieve a first individual Well-Controlled week was 16 days for Seretide compared to 37 days for the ICS group.
Estonian: Ravi kestus, mille jooksul 50% uuritavatest saavutab esimese individuaalse hea kontrolliga nädala, oli SERETIDE puhul 16 päeva ja inhaleeritava kortikosteroidi puhul 37 päeva.
English: If your asthma gets worse or is not well controlled (you will feel wheezy and need more of your fast acting ‘rescue' medicine), do not increase the number of puffs of Seretide you take.
Estonian: Kui astma muutub raskemaks või te tunnete, et haigus ei ole kontrolli all (hingeldus süveneb ning te vajate järjest sagedamini hooravimi sissehingamist), ärge suurendage ise Seretide sissehingatavate annuste arvu.
English: Seretide 25/50 micrograms strength is not appropriate in adults and children with severe asthma; it is recommended to establish the appropriate dosage of inhaled corticosteroid before any fixed combination can be used in patients with severe asthma.
Estonian: SERETIDE 25/50 mikrogrammine tugevus ei sobi raske astmaga täiskasvanutele ja lastele; enne ükskõik millise fikseeritud kombinatsiooni kasutamist raskekujulise astmaga patsientidel on soovitatav kindlaks määrata inhaleeritava glükokortikosteroidi sobiv annus.
English: If your symptoms are well controlled using Seretide Evohaler twice daily, your doctor may decide to reduce your dose to once daily.
Estonian: Kui haigusnähud on hästi kontrollitud Seretide Evohaler'i kaks korda ööpäevas kasutamisel, võib arst vähendada manustamise sagedust ühe korrani ööpäevas.
English: Children 4 to 12 years of age Seretide 25/50 Evohaler
Estonian: 4...12-aastased lapsed Seretide 25/50 Evohaler
English: - Signs of allergy, such as itching, swelling (usually of the face, lips, tongue or throat), difficulty in breathing, wheezing or coughing (bronchospasm).
Estonian: - Allergianähud, nagu sügelus, turse (tavaliselt näo-, huulte-, keele- või kõriturse), hingamisraskus, vilisev hingamine või köha (bronhide ahenemine).
English: Your doctor will supervise your treatment more closely if you have medical conditions such as heart disease including an irregular or fast heart beat, overactive thyroid gland, high blood pressure, diabetes mellitus (Seretide may increase your blood sugar), low potassium in your blood or if you are being, or have been treated for have tuberculosis (TB).
Estonian: Teie arst jälgib teie ravi eriti põhjalikult, kui teil on mõni järgnevatest haigustest: südamehaigus, sh ebaregulaarne või kiire südametegevus, kilpnäärme ületalitlus, kõrge vererõhk, suhkurtõbi (Seretide võib tõsta veresuhkru taset), madal kaaliumisisaldus veres või kui saate või olete saanud ravi tuberkuloosi vastu.
English: The maximum licensed dose of fluticasone propionate delivered by Seretide inhaler in children is 100mcg twice daily.
Estonian: SERETIDE EVOHALER'ist manustatud flutikasoonpropionaadi maksimaalne lubatud annus lastele on 100 µg kaks korda ööpäevas.
English: The results of this study suggest that Seretide 50/100mcg bd may be considered as initial maintenance therapy in patients with moderate persistent asthma for whom rapid control of asthma is deemed essential (see section 4.2).
Estonian: Uuringu tulemused näitavad, et SERETIDE EVOHALER´it annuses 50/100 mikrogrammi päevas, võib kasutada mõõduka persisteeruva astma esmaseks püsiraviks patsientidel, kellel kiire astma kontrolli alla saamist peetakse väga oluliseks (vt lõik 4.2).
English: WHAT SERETIDE IS AND WHAT IT IS USED FOR
Estonian: MIS RAVIM ON SERETIDE EVOHALER JA MILLEKS SEDA KASUTATAKSE
English: Very rare: means that fewer than 1 in 10,000 people taking the medicine are affected.
Estonian: Väga harv: kõrvaltoime tekib vähem kui 1 kasutajal 10000-st
English: Administration of Seretide to pregnant women should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.
Estonian: SERETIDE kasutamine raseduse ajal tuleb kõne alla vaid juhul, kui oodatav kasu emale on suurem kui võimalikud ohud lootele.
English: The recommendation included in section 4.2 allows a short term trial of Seretide Evohaler in adults and adolescents with moderate persistent asthma for whom rapid control of asthma is essential.
Estonian: Punktis 4.2 esitatud soovitus võimaldab Seretide Evohaleri lühiajalist testimist mõõduka persistentse astmaga täiskasvanutel ja noorukitel, kelle puhul on väga oluline allutada astma kiiresti ravile.
English: As with all inhaled medication containing corticosteroids, Seretide should be administered with caution in patients with pulmonary tuberculosis.
Estonian: Nagu ka teiste inhaleeritavate glükokortikosteroidide puhul, tuleb ettevaatlik olla ravimi manustamisel kopsutuberkuloosiga patsientidele.
English: Glaxo SmithKline Pharma GmbH Albert Schweitzer Gasse 6 1140 Wien
Estonian: Glaxo SmithKline Pharma GmbH, Albert Schweitzer Gasse 6, 1140 Wien, Austria
English: Seretide Evohaler is for inhalation use only.
Estonian: Seretide Evohaler'it manustatakse ainult inhaleerimise (sissehingamise) teel.
English: This possibility of residual impairment should always be borne in mind in emergency and elective situations likely to produce stress, and appropriate corticosteroid treatment must be considered.
Estonian: Neerupealiste funktsiooni võimaliku langusega tuleb arvestada ka erakorralistes või plaanilistes stresisituatsioonides ning kaaluda sobiva glükokortikosteroidravi kasutamist.
English: Symptomatic candidiasis can be treated with topical antifungal therapy whilst still continuing with the Seretide Evohaler.
Estonian: Sümptomaatilist kandidoosi võib ravida lokaalsete seentevastaste ravimitega, jätkates samal ajal ravi SERETIDE'ga.
English: Seretide Evohaler and associated names (see Annex I of Opinion) contain salmeterol and fluticasone propionate, a fixed dose combination of the long acting β-agonist (LABA) salmeterol and the inhaled corticosteroid (ICS) fluticasone propionate (FP) indicated in the regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and ‘as needed' inhaled short acting beta-2-agonist or - patients already adequately controlled on both inhaled corticosteroid and longacting beta-2-agonist.
Estonian: Seretide Evohaler ja sarnased nimetused (vt arvamuse I lisa) sisaldavad salmeterooli ja flutikasoonpropionaati - pika toimeajaga beetaagonisti (LABA) salmeterooli ja sissehingatava kortikosteroidi (ICS) flutikasoonpropionaadi (FP) fikseeritud dooside kombinatsiooni, mis on näidustatud astma tavaraviks, kui liittoote (pika toimeajaga beeta2-agonist ja sissehingatav kortikosteroid) kasutamine on asjakohane: - patsientidel, kes ei allu hästi ravile sissehingatavate kortikosteroididega ja „vajadusel“ lühikese toimeajaga sissehingatava beeta2-agonistiga; võipatsientidel, kes alluvad juba tõestatult hästi ravile sissehingatavate kortikosteroidi ja pika toimeajaga beeta2-agonistiga manustatuna koos.
English: GlaxoSmithKline (Ireland) Limited Stonemasons Way Rathfarnham, Dublin 16
Estonian: GlaxoSmithKline (Ireland) Limited (trading as: Allen & Hanbury) Stonemasons Way Rathfarnham
English: No ICS (SABA alone) Low dose ICS ( ≤500mcg BDP or equivalent/day) Medium dose ICS (>500-1000mcg BDP or equivalent/day) Pooled results across the 3 treatment levels *Well controlled asthma; occasional symptoms or SABA use or less than 80% predicted lung function plus no night-time awakenings, no exacerbations and no side effects enforcing a change in therapy **Total control of asthma; no symptoms, no SABA use, greater than or equal to 80% predicted lung function, no night-time awakenings, no exacerbations and no side effects enforcing a change in therapy.
Estonian: ICS ei kasutatud (ainult SABA) Väikeses annuses ICS (≤500 µg BDP või samaväärset päevas) Keskmises annuses ICS (>500-1000 µg BDP või samaväärset päevas) Ühendatud tulemused kolme ravitasandi lõikes *Hea kontroll: haigusnähtude esinemine või lühitoimeliste β-adrenomimeetikumide (SABA) kasutamine aeg-ajalt või kopsufunktsioon <80% normist pluss öiste ärkamiste, ägenemiste ja kõrvaltoimete, mis vajaksid ravi muutmist, puudumine.
English: Well-Controlled asthma was achieved more rapidly with Seretide than with ICS alone.
Estonian: Hea kontroll astma üle saavutati kiiremini SERETIDE kui ainult inhaleeritava kortikosteroidi kasutamisel.
English: The devices are packed in cartons of 1, 3 or 10 Evohalers.
Estonian: Seretide Evohaler aerosoolinhalaator - 1, 3 või 10 tk pakendis.
English: Seretide should be administered with caution in patients with severe cardiovascular disorders, including heart rhythm abnormalities, diabetes mellitus, untreated hypokalaemia or thyrotoxicosis.
Estonian: Ettevaatusega tuleb SERETIDE manustada raskete südame-veresoonkonna häirete (sh südame rütmihäirete), suhkurtõve, ravimata hüpokaleemia või türeotoksikoosi korral.
English: Seretide Evohaler should not be used to treat acute asthma symptoms for which a fast and short acting bronchodilator is required.
Estonian: SERETIDE ei ole ette nähtud kasutamiseks ägedate haigusnähtude korral, mille leevendamiseks vajab patsient kiire- ja lühitoimelist inhaleeritavat bronhodilataatorit.
English: Patients should be made aware that Seretide Evohaler must be used daily for optimum benefit, even when asymptomatic.
Estonian: Patsientidele tuleb selgitada, et parima terapeutilise toime saavutamiseks tuleb ravimit manustada regulaarselt, seda ka sümptomite puudumisel.
English: Seretide is contraindicated in patients with hypersensitivity to any of the active substances or to the excipient.
Estonian: Ülitundlikkus toimeainete või ravimi ükskõik millise abiaine suhtes.
English: 3705 LZ Zeist
Estonian: Huis ter Heideweg 62, 3705 LZ Zeist, Madalmaad
English: Belgium GlaxoSmithKline s.a./n.v., Rue du Tilleul 13
Estonian: Luksemburg GlaxoSmithKline s.a./n.v., Rue du Tilleul 13, B-1332 Genval, Belgia
English: Seretide is supplied to you in a metered dose inhaler which delivers your medicine in a pressurised suspension for you to inhale.
Estonian: Seretide on aerosoolinhalaator, mis väljastab ravimit inhaleeritava aerosoolina, mida te sisse hingate.
English: The doctor will prescribe the lowest strength of Seretide Evohaler that will best control your symptoms.
Estonian: Arst määrab teile väikseima toimiva annuse, mis tagab kontrolli haigusnähtude üle.
English: D-40789 Monheim Germany atmadisc mite DosierAerosol FCKW-frei 25 µg/50 µg Druckgasinhalation, Suspension
Estonian: Alfred-Nobel-Str. 10 D-40789 Monheim, Saksamaa atmadisc mite DosierAerosol FCKW-frei 25 µg/50 µg Druckgasinhalation, Suspension
English: D-40789 Monheim Germany atmadisc Dosier-Aerosol FCKW-frei 25 µg/125 µg Druckgasinhalation, Suspension
Estonian: Alfred-Nobel-Str. 10 D-40789 Monheim, Saksamaa atmadisc Dosier-Aerosol FCKW-frei 25 µg/125 µg Druckgasinhalation, Suspension
English: GOAL showed more patients treated with Seretide achieved asthma control than patients treated with ICS alone and this control was attained at a lower corticosteroid dose.
Estonian: GOAL uuring näitas, et kontrolli astma üle saavutas rohkem SERETIDE´t kui ainult inhaleeritavat kortikosteroidi saanud patsiente.
English: There are no data available for use of Seretide in patients with hepatic impairment.
Estonian: Puuduvad andmed SERETIDE kasutamise kohta maksapuudulikkuse korral.
English: What Seretide contains - The active substance(s) are 25 micrograms salmeterol (as xinafoate) and 50, 125 or 250
Estonian: - Toimeained on 25 mikrogrammi salmeterooli (salmeteroolksinafoaadina) ja 50, 125 või
English: PHARMACEUTICAL FORM Pressurised inhalation, suspension.
Estonian: Druckgasinhalation, Suspension
English: Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma.
Estonian: Võimalikud süsteemsed toimed on järgmised: Cushingi sündroom, Cushingi sündroomile sarnased sümptomid, neerupealiste supressioon, kasvupeetus lastel ja noorukitel, luu mineraalse tiheduse vähenemine, katarakt ja glaukoom.
English: Each puff provides 25 micrograms of salmeterol (as xinafoate) together with either 50, 125 or 250 micrograms of fluticasone propionate.
Estonian: Üks annus sisaldab 25 µg salmeterooli (salmeteroolksinafoaadina) ja 50, 125 või 250 µg flutikasoonpropionaati.
English: D-40789 Monheim Germany atmadisc forte DosierAerosol FCKW-frei 25 µg/250 µg Druckgasinhalation, Suspension
Estonian: Alfred-Nobel-Str. 10 D-40789 Monheim, Saksamaa atmadisc forte DosierAerosol FCKW-frei 25 µg/250 µg
English: Belgium GlaxoSmithKline s.a./n.v.
Estonian: GlaxoSmithKline B.V.
English: In these cases, the recommended initial dose is two inhalations of 25 micrograms salmeterol and 50 micrograms fluticasone propionate twice daily.
Estonian: Sellistel juhtudel on soovitatavaks algannuseks üks kaks inhalatsiooni 2550 mikrogrammi salmeterooli ja 50100 mikrogrammi flutikasoonpropionaati kaks korda päevas.
English: Just after starting to breathe in through their mouth, patients should press down on the top of the inhaler to release Seretide, while still breathing in steadily and deeply.
Estonian: Patsiendid peavad suu kaudu sügavalt ja ühtlaselt sisse hingama ning samal ajal vajutama ravimiannuse manustamiseks inhalaatorile.
English: Read the package leaflet before use Inhalation use
Estonian: MIDA ON VAJA TEADA ENNE SERETIDE KASUTAMIST
English: CLINICAL PARTICULARS 4.1 Therapeutic indications Seretide is indicated in the regular treatment of asthma where use of a combination product (longacting beta-2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and ‘as needed' inhaled short acting beta-2-agonist or patients already adequately controlled on both inhaled corticosteroid and long-acting beta-2-agonist.
Estonian: - inhaleeritavad glükokortikosteroidid ja „vastavalt vajadusele“ inhaleeritav lühitoimeline β2adrenomimeetikum ei taga piisavat kontrolli astmanähtude üle või - on juba saavutatud piisav kontroll inhaleeritava glükokortikosteroidi ja pikatoimelise β2adrenomimeetikumiga.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Seretide Evohaler and associated names (see Annex I) 25/125 microgram/dose pressurised inhalation, suspension [See Annex I - To be completed nationally]
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) SERETIDE EVOHALER ja sarnased nimetused (vt lisa I), 25/125 mikrogrammi/annus, inhaleeritav aerosool, suspensioon [Vt lisa I - täidetakse riiklikult]
English: A short term trial of Seretide may be considered as initial maintenance therapy in adults or adolescents with moderate persistent asthma (defined as patients with daily symptoms, daily rescue use and moderate to severe airflow limitation) for whom rapid control of asthma is essential.
Estonian: Mõõduka persisteeruva astmaga patsientideltäiskasvanutel või noorukitel, kellel on oluline kiire astmahoo kontrolli alla saamine, võib SERETIDE 12-nädalast lühiajalist kasutamist proovimist arvestada kui esialgselt püsiravi.
English: Seretide Evohaler and associated names (see Annex I) 25/125 microgram/dose pressurised inhalation, suspension
Estonian: Seretide Evohaler ja sarnased nimetused (vt lisa I), 25/125 mikrogrammi/annus, inhaleeritav aerosool, suspensioon
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each single actuation of Seretide provides:
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS
English: Seretide Evohaler and associated names (see Annex I) 25/125 microgram/dose pressurised inhalation, suspension [See Annex I - To be completed nationally]
Estonian: SERETIDE EVOHALER ja sarnased nimetused (vt lisa I), 25/125 mikrogrammi/annus, inhaleeritav aerosool, suspensioon [Vt lisa I - täidetakse riiklikult]
English: METHOD OF ADMINISTRATION Shake well before use Read the package leaflet before use
Estonian: Enne ravimi kasutamist lugege pakendi infolehte.